WO2012009347A3 - Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 - Google Patents
Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 Download PDFInfo
- Publication number
- WO2012009347A3 WO2012009347A3 PCT/US2011/043694 US2011043694W WO2012009347A3 WO 2012009347 A3 WO2012009347 A3 WO 2012009347A3 US 2011043694 W US2011043694 W US 2011043694W WO 2012009347 A3 WO2012009347 A3 WO 2012009347A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bbc3
- binding component
- inhibition
- treatment
- related diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of BCL2 binding component 3 (BBC3), in particular, by targeting natural antisense polynucleotides of BCL2 binding component 3 (BBC3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BBC3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36353510P | 2010-07-12 | 2010-07-12 | |
US61/363,535 | 2010-07-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012009347A2 WO2012009347A2 (en) | 2012-01-19 |
WO2012009347A3 true WO2012009347A3 (en) | 2012-04-26 |
Family
ID=45470031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/043694 WO2012009347A2 (en) | 2010-07-12 | 2011-07-12 | Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW201209163A (en) |
WO (1) | WO2012009347A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3260540A1 (en) | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
AP2014008100A0 (en) | 2012-05-16 | 2014-12-31 | Gen Hospital Corp | Compositions and methods for modulating hemoglobingene family expression |
EP2850186B1 (en) | 2012-05-16 | 2018-12-19 | Translate Bio MA, Inc. | Compositions and methods for modulating smn gene family expression |
AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
US10058623B2 (en) | 2012-05-16 | 2018-08-28 | Translate Bio Ma, Inc. | Compositions and methods for modulating UTRN expression |
BR112014028644A2 (en) | 2012-05-16 | 2017-08-15 | Rana Therapeutics Inc | COMPOSITIONS AND METHODS FOR MODULATION OF ATP2A2 EXPRESSION |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
CA3042401A1 (en) | 2016-11-01 | 2018-05-11 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030059776A1 (en) * | 2001-09-17 | 2003-03-27 | Immunogen Inc. | bbc3 gene promoter and methods for identifying modulators of apoptosis and bbc3 gene expression using a bbc3 gene promoter |
EP1542016A1 (en) * | 2003-12-11 | 2005-06-15 | Institut Gustave Roussy | PUMA, phosphorylated p53 and p38 map kinase as markers for HIV-1-induced apoptosis in circulating T cells of infected patient |
US20050260646A1 (en) * | 2004-04-09 | 2005-11-24 | Genomic Health Inc. | Gene expression markers for predicting response to chemotherapy |
US20060292695A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells |
-
2011
- 2011-07-12 WO PCT/US2011/043694 patent/WO2012009347A2/en active Application Filing
- 2011-07-12 TW TW100124653A patent/TW201209163A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030059776A1 (en) * | 2001-09-17 | 2003-03-27 | Immunogen Inc. | bbc3 gene promoter and methods for identifying modulators of apoptosis and bbc3 gene expression using a bbc3 gene promoter |
EP1542016A1 (en) * | 2003-12-11 | 2005-06-15 | Institut Gustave Roussy | PUMA, phosphorylated p53 and p38 map kinase as markers for HIV-1-induced apoptosis in circulating T cells of infected patient |
US20050260646A1 (en) * | 2004-04-09 | 2005-11-24 | Genomic Health Inc. | Gene expression markers for predicting response to chemotherapy |
US20060292695A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells |
Non-Patent Citations (2)
Title |
---|
"'pSUPER RNAi System; A Vector System for Expression of Short Interfering RNA'", CATALOG # VEC-PRT-0002, LABORATORY PROTOCOL FOR PSUPER.RETRO.PURO BY DNAENGINE CO., 1 May 2003 (2003-05-01) * |
JEAN-LUC PERFETTINI ET AL.: "NF-kB and p53 Are the Dominant Apoptosis- inducing Transcription Factors Elicited by the HIV-1 Envelope", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 199, no. 5, 1 March 2004 (2004-03-01), pages 629 - 640, XP002289460, DOI: doi:10.1084/jem.20031216 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012009347A2 (en) | 2012-01-19 |
TW201209163A (en) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012009347A3 (en) | Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 | |
WO2010129746A3 (en) | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp | |
WO2010129861A3 (en) | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family | |
WO2011085347A3 (en) | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg | |
WO2012054723A3 (en) | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua | |
WO2010151671A3 (en) | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 | |
WO2011090741A3 (en) | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 | |
WO2011103528A3 (en) | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 | |
WO2011091390A3 (en) | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 | |
WO2010065787A3 (en) | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene | |
WO2011150005A3 (en) | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 | |
WO2010107733A3 (en) | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 | |
WO2011082409A3 (en) | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 | |
WO2011163499A3 (en) | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna | |
WO2011143640A3 (en) | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 | |
WO2012024478A3 (en) | Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt | |
WO2011079263A3 (en) | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 | |
WO2011123745A3 (en) | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 | |
WO2011022606A3 (en) | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip | |
WO2011090740A3 (en) | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 | |
WO2012009402A3 (en) | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg | |
WO2012047956A3 (en) | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 | |
WO2012071238A3 (en) | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog | |
WO2010107740A8 (en) | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 | |
WO2010148050A3 (en) | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11807390 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11807390 Country of ref document: EP Kind code of ref document: A2 |